SBIO - ALPS Medical Breakthroughs ETF
|Ex-Dividend Date||Dec 19, 2019|
|Trading Day||April 21|
|Day's Range||46.76 - 48.56|
|52-Week Range||36.00 - 64.04|
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
|Asset Class |
|Inception Date |
Dec 31, 2014
|Ticker Symbol |
|Index Tracked |
Poliwogg Medical Breakthroughs Index
Top 10 Holdings29.72% of assets
|Dec 19, 2019||$0.016||Dec 27, 2019|
|Dec 20, 2018||$0.784||Dec 27, 2018|
|Dec 21, 2017||$0.579||Dec 28, 2017|
Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthr...
We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.
Already off to a strong start in 2021, the ALPS Medical Breakthroughs ETF (SBIO) extended the good vibes by jumping 9% in the first full trading week of February. SBIO focuses on small- and mid-cap comp...
Clinical trials are of the utmost importance to biotechnology investors, but not all exchange traded funds adequately address the phenomenon. The ALPS Medical Breakthroughs ETF (SBIO) takes a different ...
Large cap biotechnology companies are flush with cash, and they're on the prowl for takeover targets, a scenario that could bode well for the ALPS Medical Breakthroughs ETF (SBIO). SBIO focuses on small...
After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
The Food and Drug Administration (FDA) appears likely to be active on the drug review front in the months, with COVID-19 in the way. Expect that activity could benefit exchange traded funds with exposur...
Following presidential elections, biotechnology stocks and exchange traded funds often rally. If that historical precedent holds true to form, ETFs such as the ALPS Medical Breakthroughs ETF (SBIO), cou...
Historically, biotechnology stocks and exchange traded funds thrive when elections are completed. And while the winner of the presidential race isn't crystal clear, the ALPS Medical Breakthroughs ETF (S...
Wall Street registered its first back-to-back monthly loss of this year, with Dow Jones closing out the worst month since March.
With election year in the rearview mirror, 2021 could bring upside for biotechnology stocks and exchange traded funds if historical trends hold true to form. That would be a boon for the ALPS Medical Br...
By ALPS Funds SBIO ON AN ALL-TIME HIGH, TRUMPING JULY’S PEAK While broader equity markets rallied last week, the ALPS Medical Breakthroughs ETF (SBIO) rallied over 10% to surpass its previous all-time h...
The healthcare sector, biotechnology stocks included, are often politically sensitive and that sensitivity is elevated in presidential election years. That scenario is repeating this year, but investors...
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
Biotechnology stocks and exchange traded funds recently retreated as some of the air came out of the coronavirus vaccine trade and amid election year jitters.
By ALPS Funds Last week, the ALPS Medical Breakthroughs ETF (SBIO) posted gains of around 1% and outperformed broader equity markets as well as large-cap biotech indices. Valuations for SBIO’s small-to-...
The technology sector is often viewed as the epicenter of disruption and innovation, but the healthcare sector isn’t far behind and the ALPS Medical Breakthroughs ETF (SBIO) is one of the preferred idea...
The ALPS Medical Breakthroughs ETF (SBIO) is higher by almost 39% over the past 90 days. Importantly, that impressive move is underpinned by strong fundamentals throughout the broader healthcare sector.
Already one of the ETFs at the center of the coronavirus investment thesis, the ALPS Medical Breakthroughs ETF (SBIO) could be poised for more upside as the U.S. grapples with a second wave of the respi...
On Friday, FTSE Russell, one of the largest providers of benchmarks used by providers of index funds and ETFs, reshuffles its widely followed indexes, including the Russell 1000 and Russell 2000, among ...
Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish th...
In the world of biotechnology stocks and ETFs, investors are pumping up those names with exposure to coronavirus treatments and vaccines.
This trio of uniquely focused exchange-traded funds could make you a lot of money.
Follow Warren Buffett???s latest COVID-19-fighting tips with these ETF strategies.
These small-cap sector ETFs have put a great show in the past month and are likely to fare better in the post-lockdown period.
The ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) was a star performer among healthcare ETFs last year and with small- and mid-cap members of that sector looking poised to renew bullish trends this ye...
Head: Why Biotech ETFs are Rising
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.
Biotech Boom Sends One ETF Flying to Close the Year
Dec.04 -- The ETF industry has something for everyone -- the ALPS Medical Breakthrough ETF (ticker: SBIO) tracks biotech and pharmaceutical names with one or more drugs in Phase two or three of FDA clin...
Small caps started to show their momentum and are trying to catch up with the large cap peers. The Russell 2000 Index hit a new 52-week high.
October has been kind to the U.S. stock market thanks to U.S.